Athersys logo
Athersys ATHX
report update icon

Quarterly report 2023-Q3
added 06-27-2026

Athersys Income Statement 2022-2008 | ATHX

Brief overview of income trends at Athersys

The figures are compared over a five-year interval. According to figures from Athersys, revenue changed from 17.3 million dollars to 5.5 million dollars over five years. Across the full period, sales moved by −68.2%; the average annual rate was −20.5%. The business finished the period with a smaller revenue base.

EBITDA was −15.3 million dollars at the beginning and −85.6 million dollars at the end of the period (−458.7%). Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −88.3% to −1553%. The business retained less EBITDA from each unit of revenue.

The final result was −$15.3 million initially and −$87 million in the final year. The period ended with a larger loss than it began with.

Summary assessment

The indicators point to a weaker financial profile. The most visible risks are lower net income, pressure on operating profitability and a softer top-line trend. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Athersys

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

- 8.07 M 15.3 M 182 M 204 M 154 M 102 M 146 M 199 M 218 M 49.8 M 46.9 M - - -

Shares

11.9 M 8.97 M 7.5 M 152 M 137 M 112 M 84.7 M 82.1 M 77 M 57.7 M 32.6 M 23.2 M 18.9 M - -

Historical Prices

- 0.9 2.04 1.2 1.49 1.37 1.2 1.78 2.59 3.78 1.53 2.02 - - -

Net Income

-72.5 M -87 M -78.8 M -44.6 M -24.3 M -32.2 M -15.3 M -16.4 M -22.1 M -30.7 M -14.7 M -13.7 M -11.4 M -15.4 M -

Revenue

5.32 M 5.51 M 1.44 M 5.63 M 24.3 M 3.71 M 17.3 M 11.9 M 1.62 M 2.44 M 8.71 M 10.3 M - - -

Gross Profit

- - 1.44 M - - - - 11.9 M 1.62 M 2.44 M 8.71 M 10.3 M - - -

Operating Income

-77 M -87.1 M -78.3 M -45.5 M -25 M -33.3 M -15 M -17.2 M -29 M -24.5 M -16 M -13.8 M -11.5 M -15.6 M -

Interest Expense

278 K 103 K -433 K 906 K 762 K 314 K 209 K -61 K 86 K 38 K -1.14 M -778 K -69 K -126 K -

EBITDA

-75.6 M -85.6 M -77.4 M -44.8 M -24.2 M -32.6 M -14.6 M -16.9 M -28.7 M -24.1 M -15.7 M -13.5 M -11.2 M -15.4 M -

Operating Expenses

- - 79.8 M 51.1 M 50 M 37 M 33.1 M 29.1 M 30.6 M 26.9 M 24.7 M 24.1 M - - -

General and Administrative Expenses

15.9 M 20.1 M 15.9 M 11.4 M 10.4 M 8.47 M 7.84 M 7.54 M 6.91 M 6.06 M 4.75 M 4.92 M 5.39 M 5.62 M -

All numbers in USD currency

Quarterly Income Statement Athersys

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

24.5 M 20.7 M 18.3 M 18 M 11.9 M 260 M 244 M 9.71 M 229 M 222 M 208 M 202 M 197 M 191 M 163 M 160 M 153 M 150 M 146 M 144 M 139 M 138 M 127 M 122 M 115 M 112 M 102 M 86.6 M 84.9 M 84.3 M 83.8 M 83.7 M 83.1 M 82.8 M 79.2 M 77.7 M 77.3 M 77.1 M 75.9 M 70.7 M 57.6 M 56 M 53.5 M 53.1 M 29.8 M 29.4 M 29.4 M 24.5 M 23.5 M 23.5 M 24.5 M

Net Income

-3.77 M -12.9 M -7.81 M - -13.7 M -45.9 M -22.2 M -21.7 M -65.2 M -49.1 M -26.5 M -22.2 M -56.6 M -34 M -15.6 M -9.92 M -34.7 M -22.6 M -13 M -11.3 M -9.74 M 6.93 M -10.2 M -13.1 M -7.24 M -6.27 M -5.63 M -7.13 M -6 M -6.96 M 4.75 M 3.59 M -6.5 M -1.04 M -12.5 M -6.55 M -4.72 M 675 K -11.5 M -9.8 M -5.61 M -5.95 M -9.39 M -3.24 M -3.45 M -3.71 M -4.34 M -4.25 M -2.34 M -3.22 M -3.93 M

Revenue

- 49 K - - 65 K 2.32 M 2.91 M 722 K 4.79 M - - 1.27 M 86 K 84 K - 287 K -361 K 4.26 M 1.44 M 1.51 M 2.32 M 19.4 M 1.07 M 1.17 M 399 K 669 K 1.47 M 983 K 311 K 595 K 15.5 M 10.6 M 396 K 216 K 731 K 235 K 293 K 388 K 707 K 920 K 621 K 571 K 326 K 2.29 M 1.02 M 2.66 M 2.75 M 2.56 M 2.35 M 2.44 M 2.99 M

Operating Income

-7.78 M -13 M -7.33 M - -16.7 M -24.3 M -22.4 M -21.7 M -16.2 M -22.6 M -26.6 M -21.9 M -22.3 M -18.3 M -15.8 M -9.98 M -12.3 M -9.9 M -13.3 M -11.6 M -9.98 M 6.74 M -10.3 M -13.2 M -7.33 M -6.34 M -6.4 M - -6.21 M -7.28 M 6.71 M - -6.7 M -7.03 M -6.89 M - -7.27 M -7.29 M -7.39 M - -5.6 M -6.18 M -6.84 M - -4.25 M -3.61 M -4.16 M - -3.16 M -3.47 M -2.88 M

Interest Expense

211 K 366 K -477 K - 3.04 M 610 K 162 K - 45 K -27 K 121 K - -225 K -35 K 115 K - 327 K 213 K 304 K - 236 K 188 K 107 K - 71 K 58 K 26 K - 7 K 11 K 210 K - -79 K 42 K 15 K - 9 K 42 K 29 K - -4 K 15 K 17 K - 795 K -113 K -183 K - 809 K 212 K -1.09 M

EBITDA

-6.8 M -12.9 M -7.28 M - -16.1 M -23.6 M -22.1 M -21.7 M -16 M -21.8 M -26.3 M -21.9 M -22.1 M -18.1 M -15.6 M -9.98 M -12.2 M -9.74 M -13.1 M -11.6 M -9.78 M 6.94 M -10.1 M -13.2 M -7.16 M -6.17 M -6.23 M - -6.1 M -7.21 M 6.78 M - -6.63 M -6.97 M -6.82 M - -7.18 M -7.19 M -7.3 M - -5.52 M -6.09 M -6.76 M - -4.17 M -3.53 M -4.08 M - -3.08 M -3.4 M -2.82 M

General and Administrative Expenses

2.81 M 2.34 M 2.82 M - 3.74 M 5.16 M 4.1 M - 3.63 M 4.16 M 8.84 M - 3.7 M 4.43 M 3.47 M - 2.96 M 2.87 M 3.11 M - 2.56 M 2.38 M 2.66 M - 2.11 M 2.21 M 2.07 M - 1.83 M 1.98 M 2.01 M - 1.94 M 1.92 M 1.89 M - 1.7 M 1.83 M 1.78 M - 1.45 M 1.56 M 1.51 M - 1.08 M 1.16 M 1.26 M - 1.11 M 1.39 M 1.22 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Athersys (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 69.33 3.49 % $ 13.3 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 5.76 5.6 % $ 3.85 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.26 0.28 % $ 305 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 59.26 0.46 % $ 1.7 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 4.14 3.76 % $ 287 M britainBritain
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 29.07 9.41 % $ 2.88 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.83 4.46 % $ 10.1 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.34 4.83 % $ 951 M britainBritain
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA